Lorus' pancreatic cancer drug shows benefit
Posted on: Wednesday, 1 February 2006, 07:53 CST
TORONTO (Reuters) - Lorus Therapeutics Inc. said on Wednesday data from Phase 3 trials of its Virulizin(R) cancer treatment showed a significant survival benefit for a subgroup of patients.
The Canadian company said the finding from its exploratory analysis would not be sufficient for regulatory approval without additional clinical investigation.
Lorus said patients who remained on Virulizin(R) demonstrated a median survival of 10.9 months, compared with 7.4 months for patients on a placebo.
The late-stage trial compared Virulizin(R) plus gemcitabine to placebo plus gemcitabine for the treatment of chemonaive patients with locally advanced or metastatic pancreatic cancer, as first-line therapy.
An optional Stage 3 second-line therapy included continuation of Virulizin or placebo alone or in combination with 5-flurouracil.
The results of the Phase 3 clinical trial were presented at an international cancer meeting in Paris, France.
($1=$1.14 Canadian)
Source: REUTERS
Related Articles
- New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
- Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
- Global Access Project (GAP) Study Examining Patients' Cancer Care Experiences Featured in Journal CANCER
- BSD Medical Announces Completion of 340 Patient Cancer Study
- Colon-Tested Patients Cancer-Free at 5 Yrs
- Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
- Cancer Boost
- MRI Can Help Predict Breast Cancer Recurrence
- New MRI Data Shows Remicade(R) Significantly Decreases Spinal Inflammation in Patients With Ankylosing Spondylitis
- Using Genetics to Beat Breast Cancer
 |
 |
User Comments (0)
RSS Feeds